Open AccessPB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW‐DOSE CYTARABINE IN PATIENTS WITH HIGH‐RISK MDS AND AML ‐ EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
Author(s) -
Minarik L.,
Stopka T.,
Zemanova Z.,
Jonasova A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850552.03059.c9
Subject(s) - medicine , azacitidine , cytarabine , venetoclax , regimen , cohort , oncology , myelodysplastic syndromes , cytopenia , myeloid leukemia , leukemia , bone marrow , chronic lymphocytic leukemia , biology , dna methylation , gene expression , gene , biochemistry